LONDON, April 3, 2017 /PRNewswire/ --
How this report will benefit you Read on to discover how you can exploit the future business opportunities emerging in this sector.
In this brand new 200-page report you will receive 89 tables and 50 figures - all unavailable elsewhere.
The 200-page report provides clear detailed insight into the global inflammatory bowel diseases (IBD) drug market. Discover the key drivers and challenges affecting the market.
By ordering and reading our brand new report today you stay better informed and ready to act.
Report Scope • Global Inflammatory Bowel Diseases (IBD) Drug Market forecasts from 2017-2027
• Submarket forecasts from 2017-2027: - Biologics - Aminosalicylates - Antibiotics - Corticosteroids - Immunomodulators
To see a report overview please email Sara Peerun on [email protected]
• Revenue forecast from 2017-2027 for 17 leading products: - Humira - Remicade - Lialda - Asacol - Pentasa - Xifaxan - Cimzia - Tysabri - Simponi - Canasa/Salofalk - Entyvio - Apriso - Medrol - Neoral - Entocort - Uceris - Azulfidine
• Revenue forecasts from 2017-2027 for 11 countries: - US - Japan - Germany, France, UK, Spain and Italy (EU5) - Brazil, Russia, India and China (BRIC)
• Discussions on research and development, including drug candidates in these classes: - Interleukin (IL) inhibitors - Cell-adhesion molecule (CAM) inhibitors - TNF-alpha inhibitors - Stem cell therapies - JAK inhibitors - Toll-like receptor agonists
• Assessment of selected leading companies that hold major market shares in the inflammatory bowel diseases drug industry
• Discussions on trends in the industry and assesses strengths and weaknesses, as well as opportunities and threats (SWOT). It also analyses social, technological, economic and political factors influencing that industry and market (STEP)
Visiongain's study is intended for anyone requiring commercial analyses for the Global Inflammatory Bowel Diseases (IBD) Drug Market. You find data, trends and predictions.
Buy our report today Global Inflammatory Bowel Diseases (IBD) Drug Market Forecast 2017-2027: Aminosalicylates, Antibiotics, Corticosteroids, Immunomodulators, Biologics, Crohn's Disease, Ulcerative Colitis.
To request a report overview of this report please email Sara Peerun at [email protected] or call Tel: +44-(0)-20-7336-6100
Or click on: https://www.visiongain.com/Report/1830/Global-Inflammatory-Bowel-Diseases-(IBD)-Drug-Market-Forecast-2017-2027
List of Companies Mentioned in the Report
4SC
Abbott Laboratories
AbbVie
Ablynx
Actavis
Active Biotech
Ajinomoto
Allergan
Almirall
Amgen
Aptalis Pharmaceuticals
Astellas
AstraZeneca
Athersys
Atlantic Healthcare
Avaxia Biologics
BioLineRx
Biosafe
Boehringer Ingelheim
Calico
Celgene
Celltrion
Centocor Ortho Biotech
Coherus Biosciences
Coronado Biosciences
Cosmo Pharmaceuticals
Dr. Falk Pharma
Eddingpharm
Elan Pharmaceuticals
Epirus Biopharmaceuticals
Ferring
Forest Laboratories
Galapagos
Giaconda
Google
Harbor Biosciences
Hospira
InDex Pharmaceuticals
Infinity Pharmaceuticals
Isis Pharmaceuticals
Janssen Biotech
Johnson & Johnson
LG Sciences
MedImmune
Mochida
Mutare Health
Mylan Pharmaceuticals
Neovacs
Nisshin Kyorin
Nogra Pharma
Novartis
Oncobiologics
Ortho Biotech
Osiris Therapeutics
Otsuka
Ovamed
Palau Pharma
Pendopharm
Perrigo
Pfizer
Pharmascience
Pluristem Therapeutics
Quest Diagnostics
Ranbaxy Laboratories
Receptos
RedHill Biopharma
Reliance Life Sciences
Roche
Salix Pharmaceuticals
Sandoz
Sanofi
Santarus
Sequella
Shire Pharmaceuticals
Sigmoid Pharma
Soligenix
SonarMD
Takeda Pharmaceuticals
Teva Pharmaceutical Industries
TiGenix
Toray Industries
TxCell
UCB
Valeant
Warner Chilcott
Zydus Cadila
To see a report overview please email Sara Peerun on [email protected]
SOURCE Visiongain Ltd
Advertisement
Aminosalicylates, Antibiotics, Corticosteroids, Immunomodulators, Biologics, Crohn's Disease, Ulcerative Colitis
The global inflammatory bowel diseases (IBD) drug market is estimated at $8.5bn in 2016 and $9.5bn in 2020. Biologic therapies are expected to be the main drivers of growth in the world IBD drug market over the forecast period. In 2016, the biologics submarket generated revenues of $5.8bn, accounting for 68% of the global IBD drug market.
Advertisement
How this report will benefit you Read on to discover how you can exploit the future business opportunities emerging in this sector.
In this brand new 200-page report you will receive 89 tables and 50 figures - all unavailable elsewhere.
The 200-page report provides clear detailed insight into the global inflammatory bowel diseases (IBD) drug market. Discover the key drivers and challenges affecting the market.
By ordering and reading our brand new report today you stay better informed and ready to act.
Report Scope • Global Inflammatory Bowel Diseases (IBD) Drug Market forecasts from 2017-2027
• Submarket forecasts from 2017-2027: - Biologics - Aminosalicylates - Antibiotics - Corticosteroids - Immunomodulators
To see a report overview please email Sara Peerun on [email protected]
• Revenue forecast from 2017-2027 for 17 leading products: - Humira - Remicade - Lialda - Asacol - Pentasa - Xifaxan - Cimzia - Tysabri - Simponi - Canasa/Salofalk - Entyvio - Apriso - Medrol - Neoral - Entocort - Uceris - Azulfidine
• Revenue forecasts from 2017-2027 for 11 countries: - US - Japan - Germany, France, UK, Spain and Italy (EU5) - Brazil, Russia, India and China (BRIC)
• Discussions on research and development, including drug candidates in these classes: - Interleukin (IL) inhibitors - Cell-adhesion molecule (CAM) inhibitors - TNF-alpha inhibitors - Stem cell therapies - JAK inhibitors - Toll-like receptor agonists
• Assessment of selected leading companies that hold major market shares in the inflammatory bowel diseases drug industry
• Discussions on trends in the industry and assesses strengths and weaknesses, as well as opportunities and threats (SWOT). It also analyses social, technological, economic and political factors influencing that industry and market (STEP)
Visiongain's study is intended for anyone requiring commercial analyses for the Global Inflammatory Bowel Diseases (IBD) Drug Market. You find data, trends and predictions.
Buy our report today Global Inflammatory Bowel Diseases (IBD) Drug Market Forecast 2017-2027: Aminosalicylates, Antibiotics, Corticosteroids, Immunomodulators, Biologics, Crohn's Disease, Ulcerative Colitis.
To request a report overview of this report please email Sara Peerun at [email protected] or call Tel: +44-(0)-20-7336-6100
Or click on: https://www.visiongain.com/Report/1830/Global-Inflammatory-Bowel-Diseases-(IBD)-Drug-Market-Forecast-2017-2027
List of Companies Mentioned in the Report
4SC
Abbott Laboratories
AbbVie
Ablynx
Actavis
Active Biotech
Ajinomoto
Allergan
Almirall
Amgen
Aptalis Pharmaceuticals
Astellas
AstraZeneca
Athersys
Atlantic Healthcare
Avaxia Biologics
BioLineRx
Biosafe
Boehringer Ingelheim
Calico
Celgene
Celltrion
Centocor Ortho Biotech
Coherus Biosciences
Coronado Biosciences
Cosmo Pharmaceuticals
Dr. Falk Pharma
Eddingpharm
Elan Pharmaceuticals
Epirus Biopharmaceuticals
Ferring
Forest Laboratories
Galapagos
Giaconda
Harbor Biosciences
Hospira
InDex Pharmaceuticals
Infinity Pharmaceuticals
Isis Pharmaceuticals
Janssen Biotech
Johnson & Johnson
LG Sciences
MedImmune
Mochida
Mutare Health
Mylan Pharmaceuticals
Neovacs
Nisshin Kyorin
Nogra Pharma
Novartis
Oncobiologics
Ortho Biotech
Osiris Therapeutics
Otsuka
Ovamed
Palau Pharma
Pendopharm
Perrigo
Pfizer
Pharmascience
Pluristem Therapeutics
Quest Diagnostics
Ranbaxy Laboratories
Receptos
RedHill Biopharma
Reliance Life Sciences
Roche
Salix Pharmaceuticals
Sandoz
Sanofi
Santarus
Sequella
Shire Pharmaceuticals
Sigmoid Pharma
Soligenix
SonarMD
Takeda Pharmaceuticals
Teva Pharmaceutical Industries
TiGenix
Toray Industries
TxCell
UCB
Valeant
Warner Chilcott
Zydus Cadila
To see a report overview please email Sara Peerun on [email protected]
SOURCE Visiongain Ltd
